GS101
/ Jiangsu Genscend Biopharmaceutical
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 18, 2026
A Phase 1 Study of GS101 Injection to Dupixent®
(clinicaltrials.gov)
- P1 | N=294 | Not yet recruiting | Sponsor: Jiangsu Genscend Biopharmaceutical Co., Ltd
New P1 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology
1 to 1
Of
1
Go to page
1